| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 17, 2022 | New therapeutic option to reduce risk of cardiovascular deaths and repeated hospitalizations among adult heart failure patients approved in Singapore | Over the course of the VICTORIA study, there was a 4.2% reduction in annualized absolute risk with VERQUVO™ (vericiguat) compared with placebo in reducing the risk of cardiovascular death or heart failure (HF) hospitalization in adults with... |
| Apr 1, 2022 | Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024 | Leaps by Bayer, the venture capital arm of the Big Pharma, is looking to catapult itself into the future by committing more than €1.3 billion in new investments through 2024, more than doubling the pace of spending to date.
The new investme... |
| Feb 11, 2022 | With sotrovimab in the balance, Biogen vet reunites with George Scangos at Vir; First woman to chair PhRMA has more in store at Takeda | Johanna Friedl-Naderer
Vir Biotechnology is getting another Biogen vet to join up as the startup’s new global CBO and EVP.
While Johanna Friedl-Naderer officially doesn’t start her first C-suite role for another few weeks on March 2, she wi... |
| Feb 10, 2022 | Bayer : Receives U.S. FDA Fast Track Designation for asundexian Stroke Program | SPECIALIZED PRESS
Thursday - February 10, 2022
Not intended for U.S. and UK Media Bayer Receives U.S. FDA Fast Track Designation for asundexian Stroke Program
Berlin, February 10, 2022 - Bayer today announced that the U.S. Food and Drug Adm... |
| Feb 7, 2022 | Eric Lander 'bullied and demeaned' staff at White House science office — investigation | Eight months after execs at Tmunity told us in an exclusive report that the FDA had slapped a clinical hold on their pipeline programs after an unexpected reaction to their cell therapies killed 2 patients and forced them to suspend their c... |
| Feb 7, 2022 | Eric Lander 'bullied and demeaned' staff at White House science office — investigation | While Amgen boasted a 2% revenue boost last year, that growth was largely driven by profits from the company’s Covid-19 manufacturing deal with Eli Lilly, the company revealed in its Q4 results. To make up for declining Q4 sales, CEO Bob Br... |
| Feb 7, 2022 | Eric Lander 'bullied and demeaned' staff at White House science office — investigation | Today was Pfizer CEO Albert Bourla’s chance to relish the market success of its Covid vaccine and drug and what a fresh flow of $54 billion-plus from the pandemic franchise this year can do for the company. First on the list? The BD team is... |
| Feb 7, 2022 | Experts encourage better 'cyber hygiene' as pharma breaches skyrocket amid the pandemic | As the Covid-19 pandemic thrusts pharma companies into the public spotlight and accelerates digitization, cybersecurity experts say it also places a huge target on their backs. Now, Constella Intelligence is rep... |
| Feb 7, 2022 | Eric Lander 'bullied and demeaned' staff at White House science office — investigation | Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. Now, the biotech is laying off a large swath of its staff as it undergoes a pipeline overhaul.
Biosplice ... |
| Feb 7, 2022 | Eric Lander 'bullied and demeaned' staff at White House science office — investigation | A recent White House investigation concluded that Eric Lander, President Biden’s top science advisor, bullied and demeaned his subordinates, Politico reported.
The news dropped just hours after Politico reported th... |
| Feb 7, 2022 | Eric Lander 'bullied and demeaned' staff at White House science office — investigation | Al Sandrock has landed another post-Biogen gig for this next chapter in his biotech career following the catastrophic collapse of his campaign for Aduhelm.
The R&D expert has lined up a board post for Verge Genomics, an AI-powered start... |
| Feb 4, 2022 | Bayer : will discontinue phase II development candidate eliapixant | This press-release (German version) is protected by "doc-check"
SPECIALIZED PRESS
Friday - February 4, 2022 Bayer will discontinue phase II development candidate eliapixant
Review of development program led to reassessment of bene... |
| Feb 1, 2022 | How significant is the Bayer-Microsoft deal for agtech? The response | Editor’s Note: This post is co-authored by AFN’s editor Louisa Burwood-Taylor alongside Mark Johnson, who recently led grain trading platform GrainBridge to acquisition and was cofounder of Descartes Labs.
A few months ago, Bayer and Micros... |
| Jan 24, 2022 | FDA rejects Merck chronic cough drug, asks for more info on efficacy | A Merck drug that takes a novel approach to treating chronic cough has been rejected by the FDA as the agency called on the company to provide more information about the product candidate’s efficacy.
The request for more data was stated in ... |
| Jan 17, 2022 | Bayer : Annual Bayer Pharma Media Day 2022 | SPECIALIZED PRESS
Monday - January 17, 2022
Not intended for U.S. and UK Media Annual Bayer Pharma Media Day 2022
download
Berlin, Germany, January 17, 2022 - Bayer will host its annual Pharma Media Day on Monday, February 21st, 14.30h - 17... |
| Dec 21, 2021 | Bayer : U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prevent VTE in children | SPECIALIZED PRESS
Tuesday - December 21, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
downloadBlood clots
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition... |
| Dec 17, 2021 | Bayer : receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes | SPECIALIZED PRESS
Friday - December 17, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and se... |
| Dec 3, 2021 | Bayer : Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer | SPECIALIZED PRESS
Friday - December 3, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Nov 30, 2021 | Nine digital health pioneers to join Bayer’s G4A program | Photo: filadendron/Getty Images |
| Nov 15, 2021 | Bayer : extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease | SPECIALIZED PRESS
Monday - November 15, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and se... |
| Nov 12, 2021 | CytoImmune CEO breaks down her 3 'pillars' of success; Former Novartis, Gilead exec Alessandro Riva to lead an ultra low-profile cell therapy outfit | Christina Coughlin
Christina Coughlin loves cell therapy — pretty much defining her career since her postdoc days with Carl June in Pennsylvania.
Now as the new head honcho at CytoImmune as of Wednesday, the first-time CEO ... |
| Nov 11, 2021 | New Phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction | SPECIALIZED PRESS
Wednesday - November 10, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and... |
| Nov 10, 2021 | Bayer Submits Aflibercept for regulatory approval in the EU and Japan for Retinopathy of Prematurity in premature babies | SPECIALIZED PRESS
Wednesday - November 10, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and... |
| Nov 9, 2021 | Rodrigo Santos named member of the Board of Management, Bayer AG, and President of the Crop Science division | Tuesday - November 9, 2021
Effective January 1, 2022: Rodrigo Santos named member of the Board of Management, Bayer AG, and President of the Crop Science division
Liam Condon to leave the company on December 31, 2021
more imagesdownloadRodr... |
| Nov 8, 2021 | New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy | SPECIALIZED PRESS
Monday - November 8, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Nov 5, 2021 | Bayer to present data from cardiovascular portfolio, including analyses from the comprehensive finerenone clinical trial program, VOYAGER PAD (Xarelto™) and the VICTORIA trial (Verquvo™) | SPECIALIZED PRESS
Friday - November 5, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Oct 29, 2021 | European Patent Office maintained Bayer patent on the once-daily administration of rivaroxaban (Xarelto™) | SPECIALIZED PRESS
Friday - October 29, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ser... |
| Oct 27, 2021 | Bayer to present new data from comprehensive finerenone clinical trial program | SPECIALIZED PRESS
Wednesday - October 27, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and ... |
| Sep 26, 2021 | Bayer : Middle East announces partnership with the United Nations Population Fund Egypt, to support the Ministry of Health and Population's ‘Your Right to Plan' campaign in Egypt on World Contraception Day | Sunday - September 26, 2021
Bayer Middle East and UNFPA Egypt highlight the importance of providing accessible family planning and reproductive health services to Egyptian families: Bayer Middle East announces partnership with the United Na... |
| Sep 20, 2021 | Bayer : extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease | SPECIALIZED PRESS
Monday - September 20, 2021 Bitte JavaScript aktivieren / Please enable JavaScript
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and s... |
| Sep 16, 2021 | Bayer : launches transparency register for scientific collaborations with external partners | Thursday - September 16, 2021
Launch of Bayer Science Collaboration Explorer: Bayer launches transparency register for scientific collaborations with external partners
Open access database makes new contract-based scientific collaborations ... |
| Aug 12, 2021 | UPDATED: FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough | A few months ago, Merck emerged as a clear leader among a group of drugmakers racing through the clinic with a new class of therapies for chronic cough. But it looks like the Kenilworth, NJ-based pharma will now be taking another lap.
The F... |
| Aug 5, 2021 | Bayer : strengthens drug discovery platform through acquisition of Vividion Therapeutics | Thursday - August 5, 2021 Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Acquisition strengthens Bayer's drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion's unique appr... |
| Aug 5, 2021 | Bayer: Strong growth, guidance upgrade | Thursday - August 5, 2021
Second quarter of 2021 Bayer: Strong growth, guidance upgrade
Group sales increase by 12.9 percent (Fx & portfolio adj.) to 10.854 billion euros - double-digit percentage growth (Fx & portfolio adj.) at all... |
| Jul 26, 2021 | Eyeing quick approval, AbbVie offers a close-up on their presbyopia drug data | While everyone’s tuned into the Olympic Games in Japan, Cowen analysts put drugmakers through a pentathlon of their own — and in terms of R&D execution over the last 10 years, Denmark-based Novo Nordisk $NVO took home the gold.
For the ... |
| Jul 26, 2021 | Small, struggling biotech winds up with a 3X loser as another PhIII of its lead drug collapses | Little Tonix Pharmaceuticals has run into another brick wall as its lead drug — a reformulated muscle relaxant originally approved 44 years ago — has failed another Phase III study, sending shares back into penny sto... |
| Jul 26, 2021 | UPDATED: ARCH adds FDA, biodefense expertise with appointment of Luciana Borio | Once vetted by the Biden team to lead the FDA as commissioner, Luciana Borio is now compiling quite the résumé.
Borio has now been named a venture partner at Bob Nelsen’s ARCH Venture Partners, and Nelsen told Endpoints News,... |
| Jul 26, 2021 | UPDATED: ARCH adds FDA, biodefense expertise with appointment of Luciana Borio | Biosimilars have proven time and again (although mostly in Europe) that competition works to bring down the cost of a once-pricey biologic, and can even expand its use.
J&J’s Remicade, however, has always proven to be an outlier.
Back i... |
| Jul 26, 2021 | Eyeing quick approval, AbbVie offers a close-up on their presbyopia drug data | AbbVie picked up some bonus points earlier this year as one of its pipeline adds from the $63 billion Allergan buyout hit its top-line marks. And now the researchers have produced the detailed data on the case they are making w... |
| Jul 26, 2021 | Eyeing quick approval, AbbVie offers a close-up on their presbyopia drug data | Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since launching over six years ago, hype that’s only intensified in the last 14 months following the publications of a pair of papers last spring ... |
| Jul 26, 2021 | Bayer poaches newest early R&D head from Roche; GlaxoSmithKline earns expanded nod for Shingrix | Bayer has plucked its new head of research and early development from Roche’s pRED organization, where he was doing much the same thing before making the leap.
The German pharma company announced this morning that it had ... |
| Jul 19, 2021 | Sweetch raises $20M for a personalized engagement system designed to boost health outcomes | You’ve just sat down to dinner and your wearable device reminds you to get up and get in your steps for the day. Maybe the app has a point, but odds are you’ll push the notification to the side. The founders of Sweetch, an Israeli company c... |
| Jun 29, 2021 | Bayer : launches its decarbonization program for agriculture in Europe | Tuesday - June 29, 2021
Bayer Carbon Initiative: Bayer launches its decarbonization program for agriculture in Europe
In line with the political objectives of the EU Green Deal, the program's main goal is to fight climate change by establis... |
| May 12, 2021 | BAYER AG
Bayer: successful start to 2021 | Wednesday - May 12, 2021
First quarter of 2021: Bayer: successful start to 2021
Good operational performance - sales and earnings negatively impacted by currency of 938 million euros and 337 million euros / Group sales up by 2.8 percent (Fx... |
| May 6, 2021 | Bayer : Climate FieldView™, CLAAS TELEMATICS offer easy data management to help simplify farming operations | Thursday - May 6, 2021
Data management and data transfer Climate FieldView™, CLAAS TELEMATICS offer easy data management to help simplify farming operations
Harsewinkel / Monheim, May 6, 2021 - Climate FieldView™, the flagship product of Th... |
| Apr 27, 2021 | BAYER AG
Bayer : “We're optimistic for the future” | Tuesday - April 27, 2021
CEO Werner Baumann at the Annual Stockholders' Meeting of Bayer AG: 'We're optimistic for the future'
Stable operational development in fiscal 2020 despite the COVID-19 pandemic / Dividend of 2.00 euros per share pr... |
| Apr 14, 2021 | Bayer : and SVG Ventures | THRIVE partner to tackle agriculture's grand challenge | Wednesday - April 14, 2021
Apply now for THRIVE | Bayer sustainability challenge Bayer and SVG Ventures | THRIVE partner to tackle agriculture's grand challenge
downloadThe THRIVE | Bayer Sustainability Challenge will provide today's farmer... |
| Mar 23, 2021 | BAYER AG
Bayer : receives approval for Vitrakvi™ in Japan | This press-release (German version) is protected by 'doc-check'
SPECIALIZED PRESS
Tuesday - March 23, 2021
Not intended for U.S. and UK Media Bayer receives approval for Vitrakvi™ in Japan
Precision oncology treatment Vitrakvi™ (larotrectin... |
| Mar 12, 2021 | BAYER AG
Bayer : to further strengthen expertise and international profile of its Supervisory Board | Friday - March 12, 2021
Elections at the Annual Stockholders' Meeting on April 27, 2021: Bayer to further strengthen expertise and international profile of its Supervisory Board
Fei-Fei Li and Alberto Weisser proposed as successors to Johan... |
| Mar 12, 2021 | Bayer : to further strengthen expertise and international profile of its Supervisory Board | Friday - March 12, 2021
Elections at the Annual Stockholders' Meeting on April 27, 2021: Bayer to further strengthen expertise and international profile of its Supervisory Board
Fei-Fei Li and Alberto Weisser proposed as successors to Johan... |
| Feb 25, 2021 | BAYER AG
Bayer : delivers robust performance despite pandemic – foundation laid for future growth | Thursday - February 25, 2021
Fiscal 2020: Bayer delivers robust performance despite pandemic - foundation laid for future growth
Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & por... |
| Feb 25, 2021 | Bayer : delivers robust performance despite pandemic – foundation laid for future growth | Thursday - February 25, 2021
Fiscal 2020: Bayer delivers robust performance despite pandemic - foundation laid for future growth
Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & por... |
| Feb 5, 2021 | Bayer : announces agreement with plaintiffs' counsel on class plan | Wednesday - February 3, 2021 Bayer announces agreement with plaintiffs' counsel on class plan
Motion for preliminary approval is being filed for program designed to manage and resolve future Roundup™ litigation
Leverkusen, February 3, 2021 ... |
| Feb 5, 2021 | BAYER AG
Bayer : announces agreement with plaintiffs' counsel on class plan | Wednesday - February 3, 2021 Bayer announces agreement with plaintiffs' counsel on class plan
Motion for preliminary approval is being filed for program designed to manage and resolve future Roundup™ litigation
Leverkusen, February 3, 2021 ... |
| Dec 22, 2020 | M&A in healthcare: some of the biggest deals of 2020 | Teladoc bought Livongo for $18.5B; Blackstone acquired Ancestry for $4.7B; GRAIL was bought for $8B
Despite all the turmoil that COVID, and the resulting pandemic, caused in the healthcare system over the last year, that has not stopped inv... |
| Nov 3, 2020 | BAYER AG
Bayer : Challenging third quarter – Group outlook confirmed | Tuesday - November 3, 2020
Bayer: Challenging third quarter - Group outlook confirmed
Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion eur... |
| Nov 3, 2020 | Bayer : Challenging third quarter – Group outlook confirmed | Tuesday - November 3, 2020
Bayer: Challenging third quarter - Group outlook confirmed
Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion eur... |
| Aug 18, 2020 | Corporate innovation weekly: scales for your heart | Agriculture Vertical farming
Leaps by Bayer, the impact investment arm of pharmaceutical company Bayer, and Singapore’s Temasek invested in the $30m initial funding round for Unfold, the Californian vertical farming startup. The deal will i... |
| Jan 30, 2020 | The second, first AI developed drug enters the clinic; Aprea gets breakthrough status for myelodysplastic syndromes drug | → Sumitomo Dainippon Pharma and the UK-based AI startup Exscientia are claiming to have brought the first AI-designed drug into the clinic. The two companies say they developed the molecule in less than 12 months, as Exs... |
| Jan 14, 2020 | Corporate innovation weekly: CES, AI drug discovery and customised creams | CES roundup
CES calls itself the “stage for innovation” and works as a good snapshot of what is happening across the industry. Here’s what we learned this year: Robot hands are getting really good
French startup Pollen Robotics demonstrated... |
| Oct 17, 2019 | Bayer G4A partners with Seattle startups Litesprite and Prevencio on digital health efforts | Litesprite CEO Swatee Surve (right) with her mentor Jeanne Kehern, senior vice president of digital health and innovation at Bayer. (Bayer Photo)
Two Seattle-area startups were hand-picked by Bayer for a competitive program to create novel ... |
| Sep 24, 2019 | Future Food: Klaus Kunz on how Bayer is cleaning up its act | In this episode of Future Food, AFN editor Louisa Burwood-Taylor speaks to Klaus Kunz, head of sustainability and business stewardship at German agro-pharma giant Bayer. She caught up with him on the sidelines of the Seed & Chips Innova... |
| Sep 13, 2019 | Alex Arfaei trades his analyst's post for a new role as biotech VC; Sanofi vet heads to Vifor | Too often, Alex Arfaei arrived too late.
Alex Arfaei
An analyst at BMO Capital Markets, he’d meet with biotech or pharmaceutical heads for their IPO or secondary funding and his brain, trained on a biology degree and six ... |
| Sep 12, 2019 | Bayer trims 2 top execs, shrinks management board; SpringWorks boosts size of IPO | → After welcoming J&J dealmaker Marianne De Backer to their team as BD chief a little more than a week ago, Bayer announced that it will be reducing the size of the company’s board of management. Hartmut Klusik and Kem... |
| Feb 26, 2019 | With $90 million in funding, the Ginkgo spinoff Motif joins the fight for the future of food | Continuing its quest to become the Amazon Web Services for biomanufacturing, Ginkgo Bioworks has launched a new spinoff called Motif Ingredients with $90 million in funding to develop proteins that can serve as meat and dairy replacements.
... |
| Nov 29, 2018 | Bayer to cut internal drug R&D work, axing hundreds of researchers while looking to partners as it unveils plan to slash 12,000 jobs | Bayer is pushing ahead with plans to restructure its drug R&D business and cut 900 research staffers as part of a broad plan to slash a total of 12,000 employees in a worldwide revamp.
Details on the changes in R&D — som... |
| Nov 19, 2018 | «Сельское хозяйство — это не rocket science, это сложней». История белоруса, который начал помогать фермерам за 10 лет до OneSoil и продал стартап Bayer | Диана Васильева Релокейт 19 ноября 2018, 09:18 «Сельское хозяйство — это не rocket science, это сложней». История белоруса, который начал помогать фермерам за 10 лет до OneSoil и продал стартап Bayer
Оставить комментарий... |
| Oct 2, 2018 | Billionaire-Backed Fund Invests in Pivot Bio’s $70m Series B to Address ‘One of Largest Sources of GHGs on Planet’ | Breakthrough Energy Ventures, the $1 billion fund focused on accelerating the world’s transition to clean energy, has invested in the $70 million Series B round for Pivot Bio. Pivot Bio is an agtech startup producing microbes that are appli... |
| Healthcare corporations Pfizer and UnitedHealthcare are among the biggest financial backers of lawmakers behind state abortion bans | Eugenio Marongiu/Getty Images; Jenny Chang-Rodriguez/Getty Images
Healthcare companies funded lawmakers behind state abortion bans set to go into effect now that Roe v. Wade has been overturned. Pharmaceutical companies that make abortion d... |
| Joyn Bio aims to solve the world's fertilizer problem with microbes | Joyn Bio is working to engineer a microbe which would allow corn, wheat and rice farmers to cut their use of nitrogen fertilizer by half while maintaining the same crop yield.
Nitrogen fertilizers are a climate problem both in the greenhous... |
| FDA rejects Merck chronic cough drug, asks for more info on efficacy | A Merck drug that takes a novel approach to treating chronic cough has been rejected by the FDA as the agency called on the company to provide more information about the product candidate’s efficacy.
The request for more data was stated in ... |
| The German giant Bayer is remaking its pharma business, betting billions on a flurry of new deals for cutting-edge science. Wall Street is still forecasting a sales dip. | Marianne De Backer, Bayer's chief business officer. Bayer This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Bayer is spending billions on cell and gene therapies to drive its pha... |
| Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M | Parkinson’s disease patients lack sufficient amounts of a neurotransmitter that plays a key role in the brain’s ability to control movement and motor coordination. While drugs are available to address this deficiency, their effectiveness wa... |
| Bayer reloads Leaps with €1.3 billion to step up investments in biotech innovation | Over the past seven years, Bayer’s investment arm has infused 50-plus companies with more than €1.3 billion. Leaps by Bayer is accelerating its dealmaking pace and Bayer is committing another €1.3 billion, which the multinational corporatio... |
| Разрабатывала атомную бомбу, распространила ГМО и возместила сотни миллионов долларов за вред здоровью: история Monsanto Статьи редакции | Monsanto начинала с производства сахарида в конце 19 века, а через 100 лет зарабатывала миллиарды на ГМО и гербицидах. В 2016 году её купила корпорация Bayer, которой позже пришлось выплатить почти $11 млрд для урегулирования судебных исков... |